More on LGND

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-25.6% Growth)
- Ratings (7.1 Score)
- Holders
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (10/29/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Ligand Pharma (NQ:LGND)
Delayed: 308.35 +1.95 (0.64%)
Prev. Close $306.40  
Open$305.36 
52 Wk High$139.79 
52 Wk Low$82.07 
Day High$309.22 
Day Low$303.93 
P/E 717.09  
EPS$0.43 
Volume76,091 

Friends, Peers and Foes (?): XOMA, MDT, OBIO, TVTX, XOMAO (more...)

Oct 15, 2026 07:00 AM Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
Oct 6, 2026 04:36 PM Form 4 LIGAND PHARMACEUTICALS For: Oct 02 Filed by: Reardon Andrew
Sep 28, 2026 03:31 PM Form 4 LIGAND PHARMACEUTICALS For: Sep 22 Filed by: Zimmermann Martine
Sep 25, 2026 03:16 AM Barclays Starts Ligand Pharma (LGND) at Overweight
Sep 24, 2026 05:22 PM Form 4 LIGAND PHARMACEUTICALS For: Sep 22 Filed by: Zimmermann Martine
Sep 24, 2026 09:54 AM Oppenheimer Reiterates Outperform Rating on Ligand Pharma (LGND)
Sep 24, 2026 07:15 AM Form 8-K LIGAND PHARMACEUTICALS For: Sep 24
Sep 24, 2026 07:01 AM Ligand strikes up to $47M financing deal with AvenCell Therapeutics
Sep 24, 2026 07:00 AM Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Sep 23, 2026 06:16 AM Citi raises Ligand Pharma price target to $397 after royalty deal
View All Articles

Entities mentioned with LGND

View All Entities